AtaiBeckley

AtaiBeckley, a psychedelic drugmaker, was acquired by Eli Lilly for $2.8 billion upfront with up to $1 billion in contingent payments. The company developed BPL-003, a psychedelic-based nasal spray for treatment-resistant depression.